Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu(Massachusetts General Hospital), Joon Oh Park(Samsung Medical Center), Baek‐Yeol Ryoo(Asan Medical Center), Chia-Jui Yen(National Cheng Kung University Hospital), Ronnie T. P. Poon(University of Hong Kong), Davide Pastorelli(Istituti di Ricovero e Cura a Carattere Scientifico), Jean-Frédéric Blanc(Hôpital Saint-André), Hyun Cheol Chung(Yonsei University Health System), Ari David Baron(California Pacific Medical Center), Túlio Pfiffer(Instituto do Câncer do Estado de São Paulo), Takuji Okusaka(Tokyo National Hospital), Kateřina Kubáčková(University Hospital in Motol), Jörg Trojan(University Hospital Frankfurt), Javier Sastre(Hospital Clínico San Carlos), Ian Chau(Royal Marsden Hospital), Shao-Chun Chang(Eli Lilly (United States)), Paolo Abada(Eli Lilly (United States)), Ling Yang(Eli Lilly (United States)), Jonathan D. Schwartz, Masatoshi Kudo(Kindai University)
Cited by 845Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis